THERAPY DOSSIER · th-25aa5692dcf6

LMN-NKA ([Lys5,MeLeu9,Nle10]-NKA(4-10))

Hormone · Metabolically stabilised neurokinin A analogue [Lys5,MeLeu9,Nle10]-NKA(4-10), a tachykinin NK2 receptor agonist. No ChEMBL record under either name form. No ClinicalTrials.gov record; the neurokinin query returned NK1-antagonist (tradipitant) and unrelated studies, excluded as opposite-direction and a different receptor.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Metabolically stabilised neurokinin A analogue [Lys5,MeLeu9,Nle10]-NKA(4-10), a tachykinin NK2 receptor agonist. No ChEMBL record under either name form. No ClinicalTrials.gov record; the neurokinin query returned NK1-antagonist (tradipitant) and unrelated studies, excluded as opposite-direction and a different receptor.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31642371 ↗2019Reported benefit

Chronic, Twice-Daily Dosing of an NK2 Receptor Agonist [Lys,MeLeu,Nle]-NKA(4-10), Produces Consistent Drug-Induced Micturition and Defecation in Chronic Spinal Rats.

RatSpinal cord injuryUnspecifiedSprague-Dawley (from MeSH indexing)Male and femaleSubcutaneous for chronic dosing; intravenous and subcutaneous for terminal testing10 ug/kg or 100 ug/kg subcutaneously for chronic dosing; 3…Chronic phase after spinal cord injury; exact interval not stated in retrieved…

Model: Chronic thoracic spinal cord injury

Twice-daily subcutaneous LMN-NKA produced rapid micturition with response rates above 90% and voiding efficiency above 80% in males and above 60% in females, and induced defecation, both remaining stable over 30 days with no tolerance or sensitisation; efficacy was higher in males.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…

LMN-NKA ([Lys5,MeLeu9,Nle10]-NKA(4-10))